loading
Theravance Biopharma Inc stock is traded at $9.33, with a volume of 112.92K. It is up +2.08% in the last 24 hours and down -0.75% over the past month. Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$9.13
Open:
$9.19
24h Volume:
112.92K
Relative Volume:
0.49
Market Cap:
$455.13M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-10.14
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
+8.00%
1M Performance:
-0.75%
6M Performance:
+5.91%
1Y Performance:
-1.48%
1-Day Range:
Value
$9.12
$9.36
1-Week Range:
Value
$8.44
$9.36
52-Week Range:
Value
$7.44
$10.90

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name
Name
Theravance Biopharma Inc
Name
Phone
650-808-6000
Name
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Name
Employee
99
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
TBPH's Discussions on Twitter

Compare TBPH with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TBPH
Theravance Biopharma Inc
9.33 455.13M 62.02M -45.65M -9.60M -0.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.62 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
583.71 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.69 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.00 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.42 26.16B 3.81B -644.79M -669.77M -6.24

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-06-24 Downgrade Leerink Partners Outperform → Market Perform
Apr-12-24 Initiated BTIG Research Buy
Jan-08-24 Downgrade Evercore ISI Outperform → In-line
May-23-22 Initiated SVB Leerink Outperform
Nov-05-21 Upgrade JP Morgan Underweight → Neutral
Sep-15-21 Downgrade JP Morgan Overweight → Underweight
Aug-25-21 Downgrade Morgan Stanley Overweight → Underweight
Aug-24-21 Downgrade Cowen Outperform → Market Perform
Oct-14-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-07-20 Initiated JP Morgan Overweight
Jun-15-20 Initiated Morgan Stanley Equal-Weight
May-13-20 Initiated Cowen Outperform
Jan-08-20 Reiterated H.C. Wainwright Buy
Nov-06-19 Upgrade Robert W. Baird Underperform → Neutral
Oct-29-19 Initiated H.C. Wainwright Buy
Mar-29-18 Resumed Piper Jaffray Overweight
Aug-17-17 Initiated Evercore ISI Outperform
Jun-16-17 Initiated Cantor Fitzgerald Overweight
May-11-17 Reiterated Needham Buy
Dec-21-16 Initiated Needham Buy
Nov-03-16 Initiated Piper Jaffray Overweight
Oct-12-16 Downgrade Robert W. Baird Neutral → Underperform
Aug-03-16 Downgrade BofA/Merrill Neutral → Underperform
Jun-20-16 Initiated Guggenheim Buy
Jun-20-16 Reiterated Leerink Partners Outperform
May-12-16 Initiated Leerink Partners Outperform
May-05-16 Downgrade BofA/Merrill Buy → Neutral
Feb-03-15 Upgrade Robert W. Baird Underperform → Neutral
View All

Theravance Biopharma Inc Stock (TBPH) Latest News

pulisher
Apr 20, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by Alliancebernstein L.P. - Defense World

Apr 20, 2025
pulisher
Apr 19, 2025

(TBPH) Trading Signals - news.stocktradersdaily.com

Apr 19, 2025
pulisher
Apr 17, 2025

Vanguard Group Inc. Lowers Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Apr 17, 2025
pulisher
Apr 14, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Position Trimmed by Corebridge Financial Inc. - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Wellington Management Group LLP Raises Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

KLP Kapitalforvaltning AS Acquires New Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

American Century Companies Inc. Acquires 8,289 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Theravance Biopharma at Jones Conference: Strategic Growth and Future Prospects - Investing.com Canada

Apr 11, 2025
pulisher
Apr 07, 2025

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting - PR Newswire

Apr 07, 2025
pulisher
Apr 03, 2025

Teacher Retirement System of Texas Takes $103,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Apr 03, 2025
pulisher
Apr 03, 2025

Theravance biopharma SVP Rhonda Farnum sells $36,000 in shares - MSN

Apr 03, 2025
pulisher
Mar 31, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conference - Longview News-Journal

Mar 31, 2025
pulisher
Mar 31, 2025

Exclusive Access: Theravance Biopharma Leadership Reveals Strategy at Jones Healthcare Conference - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

Charles Schwab Investment Management Inc. Has $2.77 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology - PR Newswire

Mar 27, 2025
pulisher
Mar 25, 2025

Bank of New York Mellon Corp Sells 5,282 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Mar 25, 2025
pulisher
Mar 25, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Price Target from Brokerages - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Q1 EPS Forecast for Theravance Biopharma Reduced by Analyst - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

(TBPH) Investment Analysis - news.stocktradersdaily.com

Mar 23, 2025
pulisher
Mar 18, 2025

Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average – What’s Next? - Defense World

Mar 18, 2025
pulisher
Mar 10, 2025

Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha

Mar 10, 2025
pulisher
Mar 08, 2025

Rhumbline Advisers Sells 3,110 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Theravance Biopharma, Inc. to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Mar 04, 2025

Zacks Research Brokers Lower Earnings Estimates for TBPH - Armenian Reporter

Mar 04, 2025
pulisher
Mar 03, 2025

What is Zacks Research’s Forecast for TBPH Q1 Earnings? - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Where are the Opportunities in (TBPH) - news.stocktradersdaily.com

Mar 02, 2025
pulisher
Mar 01, 2025

Equities Analysts Issue Forecasts for TBPH FY2028 Earnings - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

HC Wainwright Reiterates Buy Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Theravance Biopharma Reports Strong Q4 2024 Earnings - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Investor Network: Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

Research Analysts Issue Forecasts for TBPH FY2024 Earnings - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

Theravance Biopharma (NASDAQ:TBPH) Releases Earnings Results, Misses Estimates By $0.26 EPS - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Theravance's Q4 Loss In Line With Estimates, Sales Beat - Yahoo

Feb 27, 2025
pulisher
Feb 27, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025
pulisher
Feb 27, 2025

FY2024 Earnings Forecast for TBPH Issued By HC Wainwright - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

HC Wainwright Reiterates “Buy” Rating for Theravance Biopharma (NASDAQ:TBPH) - Defense World

Feb 27, 2025
pulisher
Feb 27, 2025

Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... By GuruFocus - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance

Feb 27, 2025
pulisher
Feb 27, 2025

What is HC Wainwright’s Estimate for TBPH FY2028 Earnings? - Defense World

Feb 27, 2025
pulisher
Feb 27, 2025

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates - MSN

Feb 27, 2025
pulisher
Feb 26, 2025

Theravance Biopharma Reports Record 2024 Financial Results - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Theravance Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 26, 2025
pulisher
Feb 26, 2025

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Feb 26, 2025
pulisher
Feb 26, 2025

Theravance Biopharma Inc Reports Q4 2024 Earnings: YUPELRI Sales Reach $66.7 Million, TRELEGY Milestone Achieved - GuruFocus

Feb 26, 2025
pulisher
Feb 25, 2025

Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 20 - GuruFocus

Feb 25, 2025
pulisher
Feb 25, 2025

Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 2024 Result - Yahoo Finance

Feb 25, 2025
pulisher
Feb 25, 2025

Theravance Biopharma: Strategic Milestones and Revenue Forecasts Justify Buy Rating - TipRanks

Feb 25, 2025

Theravance Biopharma Inc Stock (TBPH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$19.80
price down icon 1.75%
$70.30
price up icon 2.22%
$32.51
price up icon 0.87%
$26.24
price up icon 1.84%
$102.53
price down icon 0.01%
biotechnology ONC
$248.35
price up icon 8.46%
Cap:     |  Volume (24h):